An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children

Trial Profile

An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs GSK 2321138A (Primary) ; Hepatitis A vaccine inactivated; Pneumococcal 7-valent CRM197 vaccine conjugate; Varicella zoster virus vaccine live
  • Indications Chickenpox; Hepatitis A; Hepatitis B; Influenza virus infections; Pneumococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Mar 2018 Primary endpoint of First occurrence of RT-PCR confirmed influenza A and/or B disease of any severity due to any seasonal influenza strain has been met, according to a GlaxoSmithKline media release.
    • 06 Mar 2018 Primary endpoint of First occurrence of Reverse transcription polymerase chain reaction (RT-PCR) confirmed moderate to severe influenza A and/or B disease due to any seasonal influenza strain has been met, according to a GlaxoSmithKline media release
    • 06 Mar 2018 Results published in the GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top